Skip to main content
Erschienen in: Reactions Weekly 1/2017

01.12.2017 | Case report

Nivolumab

Suspected immune related hepatitis: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Connolly E, et al. Immune related adverse events (irAE) and disease response with nivolumab in pre-treated advanced non-small cell lung cancer (NSCLC). Annals of Oncology 28 (Suppl. 2): iii41-iii42, Apr 2017. Available from: URL: http://doi.org/10.1093/annonc/mdx085 [abstract] - Australia Connolly E, et al. Immune related adverse events (irAE) and disease response with nivolumab in pre-treated advanced non-small cell lung cancer (NSCLC). Annals of Oncology 28 (Suppl. 2): iii41-iii42, Apr 2017. Available from: URL: http://​doi.​org/​10.​1093/​annonc/​mdx085 [abstract] - Australia
Metadaten
Titel
Nivolumab
Suspected immune related hepatitis: case report
Publikationsdatum
01.12.2017
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-017-39545-x

Weitere Artikel der Ausgabe 1/2017

Reactions Weekly 1/2017 Zur Ausgabe

Case report

Prednisolone

Case report

Crizotinib

Case report

Multiple drugs

Case report

Tocilizumab